# Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes

Study · id `cardio:ct-nct01978405` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01978405](<https://clinicaltrials.gov/study/NCT01978405>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01978405

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT01978405. Randomized; single masking; primary purpose prevention. Start 2013-11 (registry gives no type); primary completion 2014-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT01978405, source copy `cardio:ctgov-nct01978405-2013-11-08`, retrieved 2026-10-26)
- Start date: 2013-11 (registry gives no type) (ClinicalTrials.gov record NCT01978405, source copy `cardio:ctgov-nct01978405-2013-11-08`, retrieved 2026-10-26)
- Primary completion: 2014-06 (anticipated) (ClinicalTrials.gov record NCT01978405, source copy `cardio:ctgov-nct01978405-2013-11-08`, retrieved 2026-10-26)
- Completion: 2014-06 (anticipated) (ClinicalTrials.gov record NCT01978405, source copy `cardio:ctgov-nct01978405-2013-11-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01978405, source copy `cardio:ctgov-nct01978405-2013-11-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01978405-2013-11-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes
- Condition: Acute Kidney Injury
- Condition: The Changes of Plasma Creatinine
- Condition: The Changes of Plasma Free Radicals
- Condition: The Changes of Endothelium-dependent Arterial Dilation
- Intervention (Drug): Alpha lipoic acid
- Lead sponsor: Xiang Guang-da
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Xiang Guang-da (`cardio:org-xiang-guang-da`)

## Provenance

Content hash: ed0172114b2519eb9511d8b4a44262ceeb596a455128b24f79ed759c8927c4c9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
